|Bid||0.01 x 900|
|Ask||25.81 x 1000|
|Day's Range||17.33 - 17.79|
|52 Week Range||11.63 - 28.16|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||1,343.08|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Sep 12, 2001|
|1y Target Est||28.50|
ARDEN HILLS, Minn., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that it will release its 2021 third quarter results on Monday, November 8, 2021, after market close. Following the release, Intricon’s management team will host a conference call on the same day, beginning at 4:00 p.m. CT/5:00 p.m. ET.
OTC Hearing Aid Act designed to offer greater public access to hearing aids at a lower costIntricon well positioned to provide the ecosystem necessary to deliver high customer satisfaction ARDEN HILLS, Minn., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), a joint development manufacturer of micromedical technology for use in interventional, implantable, and body-worn medical devices, strongly supports the U.S. Food and Drug Administration (FDA) proposal to improve access t
It is hard to get excited after looking at IntriCon's (NASDAQ:IIN) recent performance, when its stock has declined 23...